SYNTAX score II

摘要

We welcome the opportunity to expand on how to assess the performance of the SYNTAX score II.1 First, interactions in the SYNTAX score II are central to more personalised decision making—ie, specific anatomical or clinical factors to be more predictive of mortality with percutaneous coronary intervention (PCI) compared with coronary artery bypass graft (CABG) surgery, or vice versa. All variables in the SYNTAX score II were validated, with the exception of age and left ventricular ejection fraction, which might relate to selection bias inherent to all registries. Hence randomised validation was proposed.1 Currently, validation of the SYNTAX score II is prespecified as an endpoint in the ongoing randomised EXCEL trial (NCT01205776), and the planned SYNTAX trial II which will use the SYNTAX score II to recruit patients on the grounds of patient safety.